References
- Humble JG. In vivo action of phytohaemagglutinin in severe human aplastic anemia. Nature. 1963;198:1313–4.
- Cudkowicz G, Bennett M, Shearer GM. Pluripotent stem cell function of the mouse marrow ‘lymphocyte’. Science. 1964;144:866–8.
- Fleming AF. Phytohaemagglutinin. Lancet. 1964;284:647–8.
- Scott DB, Taylor SH. Phytohaemagglutinin in aplastic anaemia. Lancet. 1967;290:991–2.
- Retief FP, Wassermann HP, Hofmeyer NG. Phytohaemagglutinin in aplastic anaemia. Lancet. 1964;284:1343–4.
- Wimer BM. PHA for aplastic anemias: the alpha but not the omega of mitogen therapies. Cancer Biother Radiopharm. 1998;13:109–20.
- Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–19.
- Chen J, Liu W, Yu W, Chen L, Wu J, Zhan Y, . A novel cell-based therapy for patients with aplastic anemia. Cytotherapy. 2010;12:678–83.
- Li G, Wang X, Wu L, Zhang W, Chen H, Xie Y, . Ex vivo activated immune cells promote survival and stimulate multilineage hematopoietic recovery in myelosuppressed mice. J Immunother. 2005;28:420–5.
- Chen J, Liu W, Wang X, Chen H, Wu J, Yang Y, . Ex vivo immunotherapy for patients with benzene-induced aplastic anemia. J Hematother Stem Cell Res. 2003;12:505–14.